Panacea settles patent dispute with US-based Celgene Corp
As per the agreement, Panacea Biotec and Apotex will receive a non-exclusive license under which the Indian firm would begin selling a generic version of Abraxane in the US15-06-2018
15-06-2018
Patent Dispute Settlement Agreement Between Panacea Biotec, Apotex And Celgene Corporation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Panacea Biotec Ltd. along with its partner, Apotex Inc. and Apotex Corp. (Apotex) have entered into a Settlement Agreement dated June 13, 2018, with Celgene Corporation, a global biopharmaceutical company headquartered in USA and its subsidiary Abraxis BioScience, LLC, for settlement of disputes regarding patents...15-06-2018
Reg.: I. Audited Financial Results (Standalone And Consolidated) For The Quarter / Year Ended 31St March, 2018 Ii. Passing Over Of Dividend For The Financial Year 2017-18
We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 30.05.2018, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Year ended 31.03.2018. The same were also reviewed by the Audit Committee in its meeting held on 29.05.2018....31-05-2018
Board Meeting On 30Th May, 2018 For Approving The Audited Financial Results For The Quarter / Financial Year Ended 31St March, 2018
Pursuant to Reg.29 of the SEBI Listing Regulations,2015 this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 30.05.2018 at New Delhi, inter-alia, to consider and approve the Audited Financial Results for the Quarter/FY ended 31.03.2018. Further, pursuant to Reg.46(2) & 47(1) of the SEBI Listing Regulations, notice of the said meeting is also being sent for publication in newspapers and uploaded on the Company''s website....16-05-2018
Shareholding for the Period Ended March 31, 2018
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here18-04-2018
Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For Half-Year Ended 31St March, 2018
Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for half-year ended 31st March, 201817-04-2018
Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 For The Half-Year Ended On 31St March, 2018
Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the half-year ended on 31st March, 201809-04-2018
Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VINOD GOELDesignation :- Company Secretary and Compliance Officer09-04-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Soshil Kumar Jain01-04-2018